Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H13N5O5 |
| Molecular Weight | 283.2407 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC2=C(N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O)C(=O)N1
InChI
InChIKey=NYHBQMYGNKIUIF-FJFJXFQQSA-N
InChI=1S/C10H13N5O5/c11-10-13-7-4(8(19)14-10)12-2-15(7)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,19)/t3-,5-,6+,9-/m1/s1
| Molecular Formula | C10H13N5O5 |
| Molecular Weight | 283.2407 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:30:57 GMT 2023
by
admin
on
Sat Dec 16 09:30:57 GMT 2023
|
| Record UNII |
0Z99WX0GPF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
135499520
Created by
admin on Sat Dec 16 09:30:57 GMT 2023 , Edited by admin on Sat Dec 16 09:30:57 GMT 2023
|
PRIMARY | |||
|
DTXSID301019130
Created by
admin on Sat Dec 16 09:30:57 GMT 2023 , Edited by admin on Sat Dec 16 09:30:57 GMT 2023
|
PRIMARY | |||
|
38819-10-2
Created by
admin on Sat Dec 16 09:30:57 GMT 2023 , Edited by admin on Sat Dec 16 09:30:57 GMT 2023
|
PRIMARY | |||
|
76352
Created by
admin on Sat Dec 16 09:30:57 GMT 2023 , Edited by admin on Sat Dec 16 09:30:57 GMT 2023
|
PRIMARY | |||
|
0Z99WX0GPF
Created by
admin on Sat Dec 16 09:30:57 GMT 2023 , Edited by admin on Sat Dec 16 09:30:57 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
EXCRETED UNCHANGED |
URINE
|
||
|
BINDER->LIGAND |
Plasma protein binding increased as ara-G concentrations increased.
BINDING
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
SINGLE DOSE ADMINISTRATION |
|
||
| Tmax | PHARMACOKINETIC |
|
SINGLE DOSE ADMINISTRATION |
|
||